TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31096977

Group type: EXPERIMENTAL
Intervention: Strong Hearts, Healthy Communities (SHHC) program, a six-month twice-weekly experiential learning lifestyle program focused on diet and physical activity (n=101)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Strong Hearts, Healthy Communities (SHHC) program
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control program (monthly healthy lifestyle education-only)
Number of subjects: 194
Study: 28666848

Group type: EXPERIMENTAL
Intervention: propofol 25 mcg/kg/h + lidocaine 1 mg/kg/h
Number of subjects: 40

Group type: COMPARATOR
Intervention: propofol 50 mcg/kg/h
Number of subjects: 40
Study: 26511605

Group type: EXPERIMENTAL
Intervention: EPICENTER care (multi-component treatment package including cognitive behavioral therapy, family psychoeducation, and metacognitive remediation)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: EPICENTER care
Number of subjects: 68
Study: 24453092

Group type: EXPERIMENTAL
Intervention: Water rinse
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Kleaner mouthwash
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Whole milk rinse
Number of subjects: 11

Group type: COMPARATOR
Intervention: Passive smoking
Number of subjects: 11
Study: 23227811

Group type: EXPERIMENTAL
Intervention: Chlorella tablets during the summer camp
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo tablets during the spring camp
Number of subjects: 10
Study: 21059322

Group type: EXPERIMENTAL
Intervention: Standardised, non-personalised dietary and lifestyle advice
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Personalised dietary and lifestyle advice, with reinforcement
Number of subjects: 154

Group type: COMPARATOR
Intervention: Prescription of laxatives (standard care control arm)
Number of subjects: 154
Study: 18197315

Group type: EXPERIMENTAL
Intervention: Mepivacaine 3% via Injex
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% with epinephrine 1:80,000 via Injex
Number of subjects: 32

Group type: COMPARATOR
Intervention: Needle injection technique
Number of subjects: 32
Study: 15522983

Group type: EXPERIMENTAL
Intervention: Pharmacist involvement in treatment
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control group (no pharmacist involvement)
Number of subjects: 235
Study: 12152676

Group type: EXPERIMENTAL
Intervention: 1 mg oral vitamin K
Number of subjects: 100

Group type: COMPARATOR
Intervention: Withholding acenocoumarol (Control)
Number of subjects: 100
Study: 9829441

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg b.i.d.
Number of subjects: 2180

Group type: COMPARATOR
Intervention: Clarithromycin 500 mg b.i.d.
Number of subjects: 2180
Study: 8131017

Group type: EXPERIMENTAL
Intervention: 2% lignocaine gel (10 ml intraurethrally)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Plain lubricating gel (10 ml)
Number of subjects: 138
Study: 2488674

Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intravenous methadone
Number of subjects: 23
Study: 88708

Group type: EXPERIMENTAL
Intervention: Midodrine (0.06 mg/kg/dose)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Etilefrin
Number of subjects: 120
Study: 31177099

Group type: EXPERIMENTAL
Intervention: CZP plus bimekizumab (240 mg loading dose then 120 mg Q2W)
Number of subjects: 79

Group type: COMPARATOR
Intervention: CZP plus placebo
Number of subjects: 79
Study: 27769783

Group type: EXPERIMENTAL
Intervention: High n‐3/n‐6 PUFAs ratio (3rd vs. 2nd tertile) in Rotterdam Study
Number of subjects: 2073

Group type: EXPERIMENTAL
Intervention: Low SFA/PUFA ratio (1st vs. 2nd tertile) in Rotterdam Study
Number of subjects: 2073

Group type: EXPERIMENTAL
Intervention: Higher n‐3/n‐6 PUFAs ratio (3rd vs. 2nd tertile) in Rotterdam Study without chronic disease
Number of subjects: 2073

Group type: EXPERIMENTAL
Intervention: Dietary fat composition (n‐3/n‐6 PUFAs ratio and SFA/PUFAs ratio)
Number of subjects: 2073

Group type: EXPERIMENTAL
Intervention: Presence of chronic disease
Number of subjects: 2073
Study: 24895062

Group type: EXPERIMENTAL
Intervention: Iosimenol 340 (0.5, 1.5 or 3.0 mL/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 24
Study: 23642948

Group type: EXPERIMENTAL
Intervention: ProstateEZE Max (herbal preparation)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 22121860

Group type: EXPERIMENTAL
Intervention: Optimal Case Management (OCM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine Case Management (RCM)
Number of subjects: 100
Study: 19705518

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (4 g daily for 8 weeks)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (200 mg daily for 8 weeks)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both omega-3 fatty acids and CoQ
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (4 g daily for 8 weeks)
Number of subjects: 85
Study: 19543733

Group type: EXPERIMENTAL
Intervention: Gated cine trueFISP MR sequence
Number of subjects: 26
Study: 15214098

Group type: EXPERIMENTAL
Intervention: Reminiscence intervention (weekly sessions)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no reminiscence intervention)
Number of subjects: 48
Study: 12185399

Group type: EXPERIMENTAL
Intervention: TRP-free amino acid mixture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nutritionally balanced amino acid drinks (Control)
Number of subjects: 0
Study: 9568182

Group type: EXPERIMENTAL
Intervention: Chemotherapy and/or radiation
Number of subjects: 137
Study: 8600700

Group type: EXPERIMENTAL
Intervention: Pinaverium bromide (50 mg, orally t.i.d with food)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2634614

Group type: EXPERIMENTAL
Intervention: 50 micrograms L-T3 (Thyrotardin)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 186223

Group type: EXPERIMENTAL
Intervention: Regular coffee (1, 2, and 4-cup equivalents)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Caffeine (4-cup equivalent)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Decaffeinated coffee (4-cup equivalent)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Regular coffee and caffeine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Regular coffee
Number of subjects: 18
Study: 11231744

Group type: EXPERIMENTAL
Intervention: Abacavir-lamivudine-zidovudine regimen
Number of subjects: 562

Group type: COMPARATOR
Intervention: Indinavir-lamivudine-zidovudine regimen
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 562
Study: 30475232

Group type: EXPERIMENTAL
Intervention: 10 mg intravenous amisulpride
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: 5 mg intravenous amisulpride
Number of subjects: 702

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 702
Study: 29499855

Group type: EXPERIMENTAL
Intervention: PF-03463275 10 mg twice a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-03463275 20 mg twice a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-03463275 40 mg twice a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-03463275 60 mg twice a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-03463275 (various doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-03463275
Number of subjects: 0
Study: 27005893

Group type: EXPERIMENTAL
Intervention: 5 days of vaginal micronized progesterone tablets (Group A)
Number of subjects: 300

Group type: COMPARATOR
Intervention: 3 days of vaginal micronized progesterone (Group B)
Number of subjects: 300
Study: 24650618

Group type: EXPERIMENTAL
Intervention: Discrete headway feedback
Number of subjects: 20

Group type: COMPARATOR
Intervention: No headway feedback (Control)
Number of subjects: 20
Study: 22278628

Group type: EXPERIMENTAL
Intervention: Azilsartan (20-40 mg once daily by forced titration)
Number of subjects: 622

Group type: COMPARATOR
Intervention: Candesartan cilexetil (8-12 mg once daily by forced titration)
Number of subjects: 622
Study: 20177043

Group type: EXPERIMENTAL
Intervention: Strategies incorporating patient perspective (exploring context, referring to mental health professional, offering alternative diagnosis)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Biomedical approaches (prescribing sleep aid or ordering diagnostic workup)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Outright rejection of request
Number of subjects: 199
Study: 18091641

Group type: EXPERIMENTAL
Intervention: 150 microg/m2 G‐CSF bis in die subcutaneously (from day 0 to day 4) in addition to standard care
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 50
Study: 15625266

Group type: EXPERIMENTAL
Intervention: StyletScope fibreoptic stylet (FOS)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Conventional metal stylet (CMS)
Number of subjects: 193
Study: 11892635

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural fentanyl (fentanyl group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normal saline (saline group)
Number of subjects: 36
Study: 9528717

Group type: EXPERIMENTAL
Intervention: Itraconazole oral solution 200 mg/day for 14 days
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Itraconazole oral solution 200 mg/day for 7 days
Number of subjects: 179

Group type: COMPARATOR
Intervention: Fluconazole tablets 100 mg/day for 14 days
Number of subjects: 179
Study: 7629001

Group type: EXPERIMENTAL
Intervention: Midaglizole (MID) 300 mg/day for 1 week
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (asthmatics not taking beta 2‐agonists)
Number of subjects: 13
Study: 2930674

Group type: EXPERIMENTAL
Intervention: i.v. ketamine 2 mg kg‐1 followed by an infusion of 2 mg kg‐1 h‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Atracurium 0.5 mg kg‐1
Number of subjects: 40
Study: 1013707

Group type: EXPERIMENTAL
Intervention: Low pressure intermittent compression (Phlebo‐Dynastat) to calves and thighs started on the day of operation and continued until patients were fully mobilized.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no treatment).
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: All patients treated with Phlebo‐Dynastat.
Number of subjects: 54
Study: 30466547

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) training
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Relational skills
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: RefCT and RefST
Number of subjects: 131
Study: 30242745

Group type: EXPERIMENTAL
Intervention: Pregabalin (150-600 mg/day for 15 weeks)
Number of subjects: 539

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 539
Study: 27060101

Group type: EXPERIMENTAL
Intervention: Eight-session self-management groups for PwD and their spouses
Number of subjects: 272

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 272
Study: 24669982

Group type: EXPERIMENTAL
Intervention: Nutrition Facts table (NFt)
Number of subjects: 3029

Group type: EXPERIMENTAL
Intervention: Traffic Light FOP system
Number of subjects: 3029

Group type: EXPERIMENTAL
Intervention: Nutrition Facts FOP system
Number of subjects: 3029

Group type: COMPARATOR
Intervention: Summary indicator systems
Number of subjects: 3029
Study: 21948599

Group type: EXPERIMENTAL
Intervention: Virtual reality‐based program (six sessions, 35‐40 minutes per session, three sessions per week)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 16
Study: 19910715

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 225

Group type: COMPARATOR
Intervention: Olanzapine plus lithium or valproate
Number of subjects: 225

Group type: COMPARATOR
Intervention: Olanzapine or olanzapine plus mood stabilizers
Number of subjects: 225

Group type: COMPARATOR
Intervention: Olanzapine or olanzapine plus lithium or valproate
Number of subjects: 225

Group type: COMPARATOR
Intervention: Comparators (placebo, lithium, placebo plus lithium or valproate)
Number of subjects: 225
Study: 17998546

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 7963

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 7963
Study: 15894149

Group type: EXPERIMENTAL
Intervention: Exercise training for 6 months
Number of subjects: 115
Study: 11561280

Group type: EXPERIMENTAL
Intervention: Ultrasound surveillance
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Selective high-risk screening
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Nonoperative management of small aneurysms
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Operative intervention
Number of subjects: 2
Study: 9389686

Group type: EXPERIMENTAL
Intervention: Filgrastim (5 microg/kg/d subcutaneously)
Number of subjects: 521

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 521
Study: 8186034

Group type: EXPERIMENTAL
Intervention: Short-wave diathermy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Megapulse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soft laser
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3367371

Group type: EXPERIMENTAL
Intervention: External reward
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Self-reward
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 153
Study: 29851439

Group type: EXPERIMENTAL
Intervention: EP phone call with mailed information
Number of subjects: 9093

Group type: EXPERIMENTAL
Intervention: Mailed information only
Number of subjects: 9093

Group type: COMPARATOR
Intervention: No educational intervention
Number of subjects: 9093
Study: 28402408

Group type: EXPERIMENTAL
Intervention: Oral azithromycin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 25644122

Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of 0.5, 1.0, or 2.0 g cefozopran hydrochloride
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Multiple intravenous doses of 2.0 g cefozopran every 12 h for 4 days
Number of subjects: 12
Study: 24219348

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 13072

Group type: EXPERIMENTAL
Intervention: Renin angiotensin system agents
Number of subjects: 13072

Group type: EXPERIMENTAL
Intervention: Dihydropyridine calcium channel blockers
Number of subjects: 13072

Group type: EXPERIMENTAL
Intervention: Overall BP medication management
Number of subjects: 13072
Study: 21255253

Group type: EXPERIMENTAL
Intervention: Prophylaxis with recombinant factor VIII (25 IU kg(‐1) 3 × week)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Episodic therapy with ≥25 IU kg(‐1) every 12‐24 h until complete clinical bleeding resolution
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Prophylaxis with recombinant factor VIII
Number of subjects: 45

Group type: COMPARATOR
Intervention: Episodic therapy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Prophylaxis started early (≤36 months)
Number of subjects: 45
Study: 17396216

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (approximately 10 g/day over three months)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (dextrose)
Number of subjects: 22
Study: 17181437

Group type: EXPERIMENTAL
Intervention: Immunization in early life
Number of subjects: 0
Study: 12925827

Group type: EXPERIMENTAL
Intervention: Air-abrasion and Carisolv gel
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional methods (local anaesthetic injection/drill)
Number of subjects: 22
Study: 11037756

Group type: EXPERIMENTAL
Intervention: Fluoride (26.3 mM NaF)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Zinc acetate (20.0 mM)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Fluoride plus zinc acetate
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Chlorhexidine diacetate (2.2 mM)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Chlorhexidine plus fluoride
Number of subjects: 11

Group type: COMPARATOR
Intervention: Water (control; treatment A)
Number of subjects: 11
Study: 9259871

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of nifedipine at 0.65 mg/h
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of nifedipine at 1.25 mg/h
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 60
Study: 8075966

Group type: EXPERIMENTAL
Intervention: Chemotherapy/radiation arm
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Hyperfractionation arm (HFX)
Number of subjects: 683

Group type: COMPARATOR
Intervention: Standard fractionation (STD)
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Karnofsky performance status (KPS) < 90 vs. > or = 90
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: T-stage
Number of subjects: 683
Study: 3316238

Group type: EXPERIMENTAL
Intervention: Early mobilisation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immobilisation for six weeks in plaster
Number of subjects: 0
Study: 31869437

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 83576

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 83576

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 83576

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 83576
Study: 29381791

Group type: EXPERIMENTAL
Intervention: Behavior Therapy (BT)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Behavior Therapy plus Meal Replacements (BT+MR)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Home Food Environment (HFE)
Number of subjects: 262
Study: 27147900

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (80 mg/m²)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Three-weekly paclitaxel (175 mg/m²)
Number of subjects: 55
Study: 24554232

Group type: EXPERIMENTAL
Intervention: Ramelteon (8 mg/d)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 22938003

Group type: EXPERIMENTAL
Intervention: Copper oxide-containing pillowcases (1% weight/weight)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control pillowcases without copper
Number of subjects: 61
Study: 20856164

Group type: EXPERIMENTAL
Intervention: JE-CV vaccine (≥4 log10 plaque forming units) administered 1 month before or after hepatitis A control vaccine
Number of subjects: 300
Study: 19035877

Group type: EXPERIMENTAL
Intervention: 400 microg inhaled salbutamol via spacer device
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2.5 mg nebulized salbutamol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 400 microg inhaled salbutamol via spacer device (corrected for heart rate)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2.5 mg nebulized salbutamol (corrected for heart rate)
Number of subjects: 20
Study: 15663493

Group type: EXPERIMENTAL
Intervention: Vitamin C (2000 mg) and Vitamin E (800 IU) daily for 7 days prior to cryotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12658400

Group type: EXPERIMENTAL
Intervention: Surgical management of pain in chronic pancreatitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparative data on treatment options
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physiological outcomes and quality-of-life issues
Number of subjects: 0
Study: 9475828

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins (LMWHs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0
Study: 8108873

Group type: EXPERIMENTAL
Intervention: ALG
Number of subjects: 117

Group type: COMPARATOR
Intervention: OKT3
Number of subjects: 117
Study: 2697116

Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine bid
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 788745

Group type: EXPERIMENTAL
Intervention: Salbutamol 250 mug
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Salbutamol 500 mug
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Salbutamol 750 mug
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Salbutamol 1000 mug
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 7
Study: 7031979

Group type: COMPARATOR
Intervention: Cough alone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Chest physiotherapy (including cough)
Number of subjects: 6
Study: 31399142

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 45

Group type: COMPARATOR
Intervention: Active control condition (regular meetings)
Number of subjects: 45
Study: 29146120

Group type: EXPERIMENTAL
Intervention: Depressive symptoms at baseline and persistence
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Repeated screening for depressive symptoms
Number of subjects: 682
Study: 26763498

Group type: EXPERIMENTAL
Intervention: Written Exposure Treatment (WET) for PTSD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-reported arousal assessments
Number of subjects: 0
Study: 27927405

Group type: EXPERIMENTAL
Intervention: Adhesive pads placed over the apex of scoliosis curves during Mehta casting
Number of subjects: 27

Group type: COMPARATOR
Intervention: No adhesive pads (non-pad group) during Mehta casting
Number of subjects: 27
Study: 21559793

Group type: EXPERIMENTAL
Intervention: Xenon anesthesia (XE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Inhalation anesthesia (SEV)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Total intravenous anesthesia (TIVA)
Number of subjects: 30
Study: 18591366

Group type: EXPERIMENTAL
Intervention: Theoretically based rape prevention intervention
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 146
Study: 16887123

Group type: EXPERIMENTAL
Intervention: 1500 mg extended-release niacin (n=20)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (n=10)
Number of subjects: 30
Study: 15080372

Group type: EXPERIMENTAL
Intervention: Daily indapamide (1 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Every other day indapamide (1 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ABPM with indapamide
Number of subjects: 30

Group type: COMPARATOR
Intervention: ABPM without indapamide
Number of subjects: 30